15
Participants
Start Date
December 31, 2009
Primary Completion Date
March 31, 2011
Study Completion Date
February 29, 2012
Stereotactic Radiosurgery (SRS)
Tumor Volume \< 2.0cm receives 24 Gy in 1 fraction Tumor Volume 2.0-2.9cm receives 18 Gy in 1 faction Tumor Volume 3.0-4.9cm receives 25 Gy in 5Gy/fraction
Bevacizumab
Bevacizumab (Avastin) 10 mg/kg given the day before SRS and 2 weeks after SRS
Duke University Medical Center, Radiation Oncology, Durham
Lead Sponsor
Collaborators (1)
Genentech, Inc.
INDUSTRY
Duke University
OTHER